Arto P.

Advances vaccine development and immunogenicity assessment for respiratory and invasive bacterial pathogens such as Respiratory Syncytial Virus, Influenza, Meningococcal disease, and Pneumococcal disease, together with emerging platforms for Cytomegalovirus, Group B Streptococcus and Yellow fever.

• RSV prophylactic vaccines
• Universal influenza vaccine candidates
• Conjugate meningococcal vaccines
• Multivalent pneumococcal conjugates
• CMV mRNA vaccine
• GBS maternal vaccine
• Live‑attenuated yellow fever vaccine

Studies encompass immunogenicity, safety, and effectiveness across infants, children, adults and older populations.

Investigates biologic and microbiome‑based interventions for systemic and organ‑specific autoimmunity, including Systemic Lupus Erythematosus, Giant cell arteritis, Ulcerative colitis and Crohn’s disease.

• IL‑17 inhibition in GCA
• B‑cell targeting in SLE
• FMT combined with biologics for ulcerative colitis
• Vedolizumab synergy in Crohn’s disease

Emphasis is placed on achieving sustained remission while reducing corticosteroid exposure.

Targets immunization strategies to protect neonates and pregnant individuals from vertically transmitted pathogens such as Group B Streptococcus and Cytomegalovirus.

• GBS vaccine administration during pregnancy
• CMV vaccine for seronegative women
• Maternal safety assessments of novel vaccines

Outcomes include transplacental antibody transfer and reduction of early‑onset neonatal disease.

Evaluates diagnostic imaging protocols for patients with compromised kidney function presenting with acute abdomen, focusing on the use of intravenous contrast CT.

• Contrast‑CT safety in eGFR 15‑45 ml/min/1.73 m²
• Diagnostic accuracy versus native CT

Goal is to optimize imaging efficacy while minimizing nephrotoxic risk.